Management of endocrine disease: Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies

European Journal of Endocrinology

Volumn 170, Issue 4, 2014, Pages

  Raverot, Gerald ^a,b,c,d   Jouanneau, Emmanuel ^a,b,c   Trouillas, Jacqueline ^a,b,c  

^a LYON NEUROSCIENCE RESEARCH CENTER   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d Service de Neurochirurgie Groupement Hospitalier Est Hospices Civils de Lyon ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MOLECULAR MARKER; PASIREOTIDE; TEMOZOLOMIDE; TRANSCRIPTOME;

CHROMOSOME ABERRATION; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS TUMOR; IMMUNOCYTOCHEMISTRY; NONHUMAN; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; TUMOR CLASSIFICATION; TUMOR RECURRENCE; TUMOR VOLUME;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADRENOCORTICOTROPIC HORMONE; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; FOLLICLE STIMULATING HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; LUTEINIZING HORMONE; PITUITARY HORMONES, ANTERIOR; PITUITARY NEOPLASMS; PROGNOSIS; PROLACTIN; PROLACTINOMA; THYROTROPIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84899487618     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-1031     Document Type: Review

References (139)

1. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775. (doi:10.1210/jc.2006-1668)
2. Fernandez A, Karavitaki N & Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 2010 72 377-382. (doi:10.1111/j.1365-2265.2009.03667.x)
3. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V & Laws ER Jr. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. Journal of Neurosurgery 2011 114 336-344. (doi:10.3171/2010.8. JNS10290)
4. Meij BP, Lopes MB, Ellegala DB, Alden TD & Laws ER Jr. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. Journal of Neurosurgery 2002 96 195-208. (doi:10.3171/jns.2002.96.2.0195)
5. Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J & Brue T. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical Endocrinology 2012 76 769-775. (doi:10.1111/j.1365-2265. 2012.04381.x)
6. McCormack AI, Wass JA & Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. European Journal of Clinical Investigation 2011 41 1133-1148. (doi:10.1111/j.1365-2362.2011.02520.x)
7. Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J & Tauveron I. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Investigation 2013 31 190-196. (doi:10.3109/07357907. 2013.775293)
8. Dudziak K, Honegger J, Bornemann A, Horger M & Mussig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course - case report and review of the literature. Journal of Clinical Endocrinology and Metabolism 2011 96 2665-2669. (doi:10.1210/jc.2011-1166)
9. Heaney A. Clinical review: Pituitary carcinoma: difficult diagnosis and treatment. Journal of Clinical Endocrinology and Metabolism 2011 96 3649-3660. (doi:10.1210/jc.2011-2031)
10. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J & Raverot G. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 2012 15 37-43. (doi:10.1007/s11102-011- 0341-0)
11. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clinical Endocrinology 2009 71 226-233. (doi:10.1111/j.1365- 2265.2008. 03487.x)
12. Raverot G, Sturm N, De Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. Journal of Clinical Endocrinology and Metabolism 2010 95 4592-4599. (doi:10.1210/jc.2010-0644)
13. Lloyd RV, Kovacs K, Young WF, Farrell WE, Asa SL, Trouillas J, Kontogeorgos G & Sano T. In Pituitary Tumours: Introduction. Lyon: IARC Press, 2004.
14. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathologica 2013 126 123-135. (doi:10.1007/s00401-013-1084-y)
15. Trouillas J & Girod C. In Pathology of Pituitary Adenomas. In Pituitary Adenomas. Editors, Landolt AM. Vance ML, Reilly PL, pp 27-46. New York: Churchill Livingstone, 1996.
16. Kovacs K, Scheithauer B, Horvath E & Lloyd RV. The WHO classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 1996 78 502-510. (doi:10.1002/(SICI) 1097-0142 (19960801) 78:3<502::AID-CNCR18>3. 0. CO;2-2)
17. Kovacs K, Horvath E, Ryan N & Ezrin C. Null cell adenoma of the human pituitary. Virchows Archiv. A, Pathological Anatomy and Histology 1980 387 165-174. (doi:10.1007/BF00430697)
18. Trouillas J, Lheritier M, Cure M, Girod C, Guinet P, Tommasi M, Goutelle A & Allegre GE. L'oncocytome hypophysaire est-il une entité? Discussion anatomo-clinique à propos de 3 observations personnelles. Lyon Médical 1975 234 25-35.
19. Kovacs K & Horvath E. Pituitary "chromophobe" adenoma composed of oncocytes. A light and electron microscopic study. Archives of Pathology 1973 95 235-239.
20. Thodou E, Argyrakos T & Kontogeorgos G. Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones 2007 6 227-232.
21. Mete O & Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathology 2012 22 443-453. (doi:10.1111/j.1750-3639.2012.00599. x)
22. Delhase M, Vergani P, Malur A, Velkeniers B, Teugels E, Trouillas J & Hooghe-Peters EL. Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours. Journal of Molecular Endocrinology 1993 11 129-139. (doi:10.1677/jme. 0.0110129)
23. Vallette-Kasic S, Figarella-Branger D, Grino M, Pulichino AM, Dufour H, Grisoli F, Enjalbert A, Drouin J & Brue T. Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs. Journal of Clinical Endocrinology and Metabolism 2003 88 3050-3056. (doi:10.1210/jc.2002-021934)
24. Asa SL, Bamberger AM, Cao B, Wong M, Parker KL & Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. Journal of Clinical Endocrinology and Metabolism 1996 81 2165-2170. (doi:10.1210/jcem.81.6.8964846)
25. Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME & Singer W. Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. American Journal of Pathology 1980 98 617-638.
26. Cooper O & Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Practice & Research. Clinical Endocrinology & Metabolism 2012 26 447-460. (doi:10.1016/j.beem.2012.01.002)
27. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M & Trouillas J. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. European Journal of Endocrinology 2010 163 35-43. (doi:10.1530/EJE-10-0076)
28. Horvath E, Kovacs K, Smith H, Cusimano M & Singer W. Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastructural Pathology 2005 29 511-524. (doi:10.1080/01913120500323514)
29. Tourniaire J, Trouillas J, Chalendar D, Bonneton-Emptoz A, Goutelle A & Girod C. Somatotropic adenoma manifested by galactorrhea without acromegaly. Journal of Clinical Endocrinology and Metabolism 1985 61 451-453. (doi:10.1210/jcem-61-3-451)
30. Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C & Weiss MH. Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 1981 47 761-771. (doi:10.1002/1097-0142 (19810215) 47:4<761::AID-CNCR2820 470422>3.0. CO;2-L)
31. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M & Yamada S. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocrine Pathology 2008 19 82-91. (doi:10.1007/s12022-008-9029-z)
32. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J & Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Hormones and Cancer 2010 1 80-92. (doi:10.1007/s12672-010- 0014-x)
33. Chinezu L, Vasiljevic A, Jouanneau E, Francois P, Borda A, Trouillas J & Raverot G. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Human Pathology 2013 45 71-77. (doi:10.1016/j.humpath. 2013.08.007)
34. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M & Grossman AB. Clinical review: Diagnosis and management of pituitary carcinomas. Journal of Clinical Endocrinology and Metabolism 2005 90 3089-3099. (doi:10.1210/jc.2004- 2231)
35. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ & Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. European Journal of Endocrinology 2007 156 203-216. (doi:10.1530/eje.1.02326)
36. Wolfsberger S & Knosp E. Comments on the WHO 2004 classification of pituitary tumors. Acta Neuropathologica 2006 111 66-67. (doi:10.1007/s00401-005- 1097-2)
37. Solcia E, Klöppel G, Sobin LH, Capella C, De Lellis RA, Heitz PU, Horvath E, Kovacs K, Lack E, Lloyd RV, Rosai J & Scheithauer BW 2000. Histological typing of endocrine tumours. 2nd Edition, WHO International Histological Classification of Tumours. Berlin: Springer Verlag.
38. Figarella-Branger D & Trouillas J. The new WHO classification of human pituitary tumors: comments. Acta Neuropathologica 2006 111 71-72. (doi:10.1007/s00401-005-1099-0)
39. Grossman A. The 2004 World health organization classification of pituitary tumors: is it clinically helpful? Acta Neuropathologica 2006 111 76-77. (doi:10.1007/s00401-005-1101-x)
40. Laws ER Jr & Lopes MB. The new WHO classification of pituitary tumors: highlights and areas of controversy. Acta Neuropathologica 2006 111 80-81. (doi:10.1007/s00401-005-1103-8)
41. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, De Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 2006 449 395-401. (doi:10.1007/s00428-006-0250-1)
42. Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M & Herbreteau D. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 2000 215 463-469. (doi:10.1148/radiology.215.2. r00ap18463)
43. Francois P, Travers N, Lescanne E, Arbeille B, Jan M & Velut S. The interperiosteo-dural concept applied to the perisellar compartment: a microanatomical and electron microscopic study. Journal of Neurosurgery 2010 113 1045-1052. (doi:10.3171/2010.1. JNS081701)
44. Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, Mazzatenta D, Farnedi A, Menetti F, Marucci G et al. A classification tree approach for pituitary adenomas. Human Pathology 2012 43 1627-1637. (doi:10.1016/j.humpath.2011.12.003)
45. Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, Lopes MB & Asa SL. Protocol for the examination of specimens from patients with primary pituitary tumors. Archives of Pathology & Laboratory Medicine 2011 135 640-646. (doi:10.1043/2010-0470-SAR1.1)
46. Amar A, Hinton D, Krieger M & Weiss M. Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 1999 2 117-122. (doi:10.1023/A:1009931413106)
47. Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B & Rohmer V. Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. European Journal of Endocrinology 2007 157 141-147. (doi:10.1530/EJE-07-0099)
48. Knosp E, Kitz K & Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 1989 25 927-930. (doi:10.1227/00006123-198912000-00012)
49. Saeger W, Lüdecke B & Lüdecke DK. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas. Experimental and Clinical Endocrinology & Diabetes 2008 116 80-85. (doi:10.1055/s-2007-991131)
50. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D & Laws ER Jr. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996 38 99-106 (discussion 106-107). (doi:10.1097/00006123- 199601000-00024)
51. Gejman R, Swearingen B & Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Human Pathology 2008 39 758-766. (doi:10.1016/j.humpath.2007.10.004)
52. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. Journal of Clinical Endocrinology and Metabolism 2010 95 1708-1716. (doi:10.1210/jc.2009-1191)
53. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr & Lloyd RV. Pituitary carcinoma: a clinicopathological review. Neurosurgery 2005 56 1066-1074 (discussion 1066-1074). (doi:10.1227/01. NEU.0000157926.72826. DB)
54. Lubke D & Saeger W. Carcinomas of the pituitary: definition and review of the literature. General & Diagnostic Pathology 1995 141 81-92.
55. Trouillas J, Chevallier P, Claustrat B, Hooghe-Peters E, Dubray C, Rousset B & Girod C. Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology 1994 134 401-410. (doi:10.1210/endo.134.1.7903933)
56. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-Related Cancer 2007 14 887-900. (doi:10.1677/ERC-07- 0062)
57. Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J & Trouillas J. Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Molecular and Cellular Endocrinology 2010 326 30-39. (doi:10.1016/j.mce.2010.02.043)
58. Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P et al. Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathology 2011 21 533-543. (doi:10.1111/j.1750-3639.2011.00476.x)
59. Gurlek A, Karavitaki N, Ansorge O & Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. European Journal of Endocrinology 2007 156 143-153. (doi:10.1530/eje.1.02339)
60. Zhu X, Asa SL & Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clinical Cancer Research 2008 14 1984-1996. (doi:10.1158/1078-0432. CCR-07-2003)
61. Ezzat S, Zheng L & Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Molecular Endocrinology 2004 18 2543-2552. (doi:10.1210/me.2004-0182)
62. Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, Jan M, Perrin G, Fischer G, Tabarin A et al. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. Journal of Neurosurgery 2003 98 1084-1093. (doi:10.3171/jns.2003.98.5. 1084)
63. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M & Maurage CA. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathology 2012 22 757-764. (doi:10.1111/j.1750-3639.2012.00578.x)
64. Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K & Kurisu K. Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochirurgica 1996 138 1442-1448. (doi:10.1007/BF01411124)
65. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD & Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1999 84 761-767.
66. Evans CO, Moreno CS, Zhan X, McCabe MT, Vertino PM, Desiderio DM & Oyesiku NM. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary 2008 11 231-245. (doi:10.1007/s11102-007-0082-2)
67. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS & Oyesiku NM. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. Journal of Clinical Endocrinology and Metabolism 2001 86 3097-3107. (doi:10.1210/jcem.86.7.7616)
68. Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM & Oyesiku NM. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Research 2005 65 10214-10222. (doi:10.1158/0008-5472. CAN-05-0884)
69. Morris DG, Musat M, Czirjak S, Hanzely Z, Lillington DM, Korbonits M & Grossman AB. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. European Journal of Endocrinology 2005 153 143-151. (doi:10.1530/eje.1.01937)
70. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B & Klibanski A. Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 2002 87 1262-1267. (doi:10.1210/jcem.87.3.8315)
71. Bahar A, Bicknell JE, Simpson DJ, Clayton RN & Farrell WE. Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 2004 23 936-944. (doi:10.1038/sj.onc.1207193)
72. Mezzomo LC, Gonzales PH, Pesce FG, Kretzmann Filho N, Ferreira NP, Oliveira MC & Kohek MB. Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas. Pituitary 2012 15 420-427. (doi:10.1007/s11102-011-0340-1)
73. Michaelis KA, Knox AJ, Xu M, Kiseljak-Vassiliades K, Edwards MG, Geraci M, Kleinschmidt-De Masters BK, Lillehei KO & Wierman ME. Identification of growth arrest and DNA-damage-inducible gene β (GADD45β) as a novel tumor suppressor in pituitary gonadotrope tumors. Endocrinology 2011 152 3603-3613. (doi:10.1210/en. 2011-0109)
74. Zhang X, Zhou Y & Klibanski A. Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach. Molecular and Cellular Endocrinology 2010 326 40-47. (doi:10.1016/j.mce.2010.02.040)
75. Zhou Y, Zhang X & Klibanski A. Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Molecular and Cellular Endocrinology 2013. pii: S0303-7207 (13) 00368-7. (doi:10.1016/j.mce.2013.09. 006)
76. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR & Klibanski A. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. Journal of Clinical Endocrinology and Metabolism 2003 88 5119-5126. (doi:10.1210/jc.2003-030222)
77. Zhao J, Dahle D, Zhou Y, Zhang X & Klibanski A. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2005 90 2179-2186. (doi:10.1210/jc.2004-1848)
78. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Ansell PJ, Zhao J, Weng C & Klibanski A. Activation of p53 by MEG3 non-coding RNA. Journal of Biological Chemistry 2007 282 24731-24742. (doi:10.1074/jbc. M702029200)
79. Farrell WE. Pituitary tumours: findings from whole genome analyses. Endocrine-Related Cancer 2006 13 707-716. (doi:10.1677/erc.1.01131)
80. Galland F, Lacroix L, Saulnier P, Dessen P, Meduri G, Bernier M, Gaillard S, Guibourdenche J, Fournier T, Evain-Brion D et al. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocrine-Related Cancer 2010 17 361-371. (doi:10.1677/ERC-10-0018)
81. Marko NF, Coughlan C & Weil RJ. Towards an integrated molecular and clinical strategy to predict early recurrence in surgically resected non-functional pituitary adenomas. Journal of Clinical Neuroscience 2012 19 1535-1540. (doi:10.1016/j.jocn. 2012.01.038)
82. Chen S, Mantei N, Dong L & Schachner M. Prevention of neuronal cell death by neural adhesion molecules L1 and CHL1. Journal of Neurobiology 1999 38 428-439. (doi:10.1002/(SICI) 1097-4695 (19990215) 38:3<428::AID-NEU10>3.0. CO;2-6)
83. Pereira AM & Biermasz NR. Treatment of nonfunctioning pituitary adenomas: what were the contributions of the last 10 years? A critical view. Annales d'Endocrinologie 2012 73 111-116. (doi:10.1016/j.ando. 2012.04.002)
84. Roelfsema F, Biermasz NR & Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 2012 15 71-83. (doi:10.1007/s11102-011-0347- 7)
85. Daniel L, Trouillas J, Renaud W, Chevallier P, Gouvernet J, Rougon G & Figarella-Branger D. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy. Cancer Research 2000 60 80-85.
86. Trouillas J, Chevallier P, Remy C, Rajas F, Cohen R, Calle A, Hooghe-Peters EL & Rousset B. Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression. Endocrinology 1999 140 13-21. (doi:10.1210/endo.140.1.6450)
87. Pei L & Melmed S. Isolation and characterization of a pituitary tumortransforming gene (PTTG). Molecular Endocrinology 1997 11 433-441. (doi:10.1210/mend.11.4.9911)
88. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV & Clayton RN. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Journal of Clinical Endocrinology and Metabolism 1997 82 818-824. (doi:10.1210/jcem.82.3.3799)
89. Harada K, Nishizaki T, Ozaki S, Kubota H, Okamura T, Ito H & Sasaki K. Cytogenetic alterations in pituitary adenomas detected by comparative genomic hybridization. Cancer Genetics and Cytogenetics 1999 112 38-41. (doi:10.1016/S0165-4608 (98) 00235-0)
90. Pack SD, Qin LX, Pak E, Wang Y, Ault DO, Mannan P, Jaikumar S, Stratakis CA, Oldfield EH, Zhuang Z et al. Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes, Chromosomes and Cancer 2005 43 72-82. (doi:10.1002/gcc.20162)
91. Rickert CH, Dockhorn-Dworniczak B, Busch G, Moskopp D, Albert FK, Rama B & Paulus W. Increased chromosomal imbalances in recurrent pituitary adenomas. Acta Neuropathologica 2001 102 615-620. (doi:10. 1007/s004010100413)
92. Rickert CH, Scheithauer BW & Paulus W. Chromosomal aberrations in pituitarycarcinomametastases. Acta Neuropathologica 2001 102 117-120.
93. Szymas J, Schluens K, Liebert W & Petersen I. Genomic instability in pituitary adenomas. Pituitary 2002 5 211-219. (doi:10.1023/A:1025313214951)
94. Trautmann K, Thakker RV, Ellison DW, Ibrahim A, Lees PD, Harding B, Fischer C, Popp S, Bartram CR & Jauch A. Chromosomal aberrations in sporadic pituitary tumors. International Journal of Cancer 2001 91 809-814. (doi:10.1002/1097-0215 (200102) 9999:9999<::AID-IJC1127>3.0. CO;2-E)
95. Amaral FC, Torres N, Saggioro F, Neder L, Machado HR, Silva WA Jr, Moreira AC & Castro M. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2009 94 320-323. (doi:10.1210/jc.2008-1451)
96. Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC & DegliUberti EC. miR-15a and miR-16-1 down-regulation in pituitary adenomas. Journal of Cellular Physiology 2005 204 280-285. (doi:10.1002/jcp. 20282)
97. Bottoni A, Zatelli MC, Ferracin M, Tagliati F, Piccin D, Vignali C, Calin GA, Negrini M, Croce CM & Degli Uberti EC. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. Journal of Cellular Physiology 2007 210 370-377. (doi:10.1002/jcp. 20832)
98. Butz H, Liko I, Czirjak S, Igaz P, Khan MM, Zivkovic V, Balint K, Korbonits M, Racz K & Patocs A. Down-regulation of Wee1 kinase by a specific subset of microRNA in human sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2010 95 E181-E191. (doi:10.1210/jc.2010-0581)
99. Butz H, Liko I, Czirjak S, Igaz P, Korbonits M, Racz K & Patocs A. MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas. Pituitary 2011 14 112-124. (doi:10.1007/s11102-010-0268-x)
100. Cheunsuchon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y, Rice KA, Tessa Hedley-Whyte E, Swearingen B & Klibanski A. Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. American Journal of Pathology 2011 179 2120-2130. (doi:10.1016/j.ajpath.2011.07.002)
101. D'Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, Fedele M, Croce CM, Trouillas J & Fusco A. Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. Journal of Clinical Endocrinology and Metabolism 2012 97 E1128-E1138. (doi:10.1210/jc.2011-3482)
102. Mao ZG, He DS, Zhou J, Yao B, Xiao WW, Chen CH, Zhu YH & Wang HJ. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagnostic Pathology 2010 5 79. (doi:10.1186/1746-1596-5-79)
103. Palmieri D, D'Angelo D, Valentino T, De Martino I, Ferraro A, Wierinckx A, Fedele M, Trouillas J & Fusco A. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 2012 31 3857-3865. (doi:10.1038/onc.2011.557)
104. Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D & Stratakis CA. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene 2013 32 1651-1659. (doi:10.1038/onc.2012.190)
105. Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, Wang EL, Rahman MM, Inoue H, Itakura M et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Modern Pathology 2009 22 431-441. (doi:10.1038/modpathol. 2008.202)
106. Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovacs G, Korbonits M, Scheithauer BW, Kovacs K & Lloyd RV. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 2010 38 67-75. (doi:10.1007/s12020-010-9346-0)
107. Trivellin G, Butz H, Delhove J, Igreja S, Chahal HS, Zivkovic V, McKay T, Patocs A, Grossman AB & Korbonits M. MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. American Journal of Physiology. Endocrinology and Metabolism 2012 303 E708-E719. (doi:10.1152/ajpendo.00546. 2011)
108. Wang L, Liu W, Jiang W, Lin J, Jiang Y, Li B & Pang D. A miRNA binding site single-nucleotide polymorphism in the 3'-UTR region of the IL23R gene is associated with breast cancer. PLoS ONE 2012 7 e49823. (doi:10.1371/journal.pone.0049823)
109. Duong CV, Emes RD, Wessely F, Yacqub-Usman K, Clayton RN & Farrell WE. Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas. Endocrine-Related Cancer 2012 19 805-816. (doi:10.1530/ERC-12-0251)
110. Beckers A, Aaltonen LA, Daly AF & Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrine Reviews 2013 34 239-277. (doi:10.1210/er.2012-1013)
111. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C & Calender A. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism 2002 87 457-465. (doi:10.1210/jcem.87.2.8145)
112. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006 312 1228-1230. (doi:10.1126/science.1126100)
113. Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. European Journal of Endocrinology 2007 157 1-8. (doi:10.1530/EJE-07-0181)
114. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Verges B et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. American Journal of Surgical Pathology 2008 32 534-543. (doi:10.1097/PAS. 0b013e31815ade45)
115. Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, Tabarin A, Nunes ML, Delemer B, Rohmer V et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. European Journal of Endocrinology 2013 168 533-541. (doi:10.1530/EJE-12-0763)
116. Oriola J, Lucas T, Halperin I, Mora M, Perales MJ, Alvarez-Escola C, Paz De MN, Diaz Soto G, Salinas I, Julian MT et al. Germline mutations of AIP geneinsomatotropinomasresistanttosomatostatinanalogues. European Journal of Endocrinology 2013 168 9-13. (doi:10.1530/EJE-12-0457)
117. Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. Journal of Clinical Endocrinology and Metabolism 2012 97 E1411-E1420. (doi:10.1210/jc.2012-1111)
118. Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, D'Innocenzo E, Barlier A, Giangaspero F, Esposito V et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocrine-Related Cancer 2009 16 1029-1043. (doi:10.1677/ERC-09-0094)
119. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research 2007 13 2986-2991. (doi:10.1158/1078-0432. CCR-06-2053)
120. Marucci G. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011 117 4101-4102 (author reply 4102). (doi:10.1002/cncr.26000)
121. Kovacs K, Scheithauer B, Lombardero M, McLendon R, Syro L, Uribe H, Ortiz L & Penagos L. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathologica 2008 115 261-262. (doi:10.1007/s00401-007-0279-5)
122. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr & Lopes MB. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O (6) - methylguanine methyltransferase (MGMT) promoter methylation and expression. Journal of Clinical Endocrinology and Metabolism 2010 95 E280-E290. (doi:10.1210/jc.2010- 0441)
123. Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H et al. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: The national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. Journal of Clinical Endocrinology and Metabolism 2013 98 1130-1136. (doi:10.1210/jc.2012-2924)
124. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ & Simmons NE. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. Journal of Neurosurgery 2006 105 621-626. (doi:10.3171/jns.2006.105.4.621)
125. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P & Reni M. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. European Journal of Endocrinology 2010 163 843-851. (doi:10.1530/EJE-10- 0629)
126. Philippon M, Morange I, Barrie M, Barlier A, Taieb D, Dufour H, Conte-Devolx B, Brue T & Castinetti F. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Annales d'Endocrinologie 2012 73 225-229. (doi:10.1016/j.ando. 2012.03.001)
127. Beauchesne P, Trouillas J, Barral F & Brunon J. Gonadotropic pituitary carcinoma: case report. Neurosurgery 1995 37 810-815 (discussion 815-816). (doi:10.1227/00006123-199510000-00027)
128. Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y & Fine RL. Temozolomide (Temodar (R)) and capecitabine (Xeloda (R)) treatment of an aggressive corticotroph pituitary tumor. Pituitary 2011 14 418-424. (doi:10.1007/s11102-009-0211-1)
129. Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP & Thome C. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Experimental and Clinical Endocrinology and Diabetes 2010 118 760-763. (doi:10.1055/s-0030-1253419)
130. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocrine-Related Cancer 2009 16 1329-1338. (doi:10.1677/ERC-09-0101)
131. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK & Theodoropoulou M. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Research 2010 70 666-674. (doi:10.1158/0008-5472. CAN-09-2951)
132. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M & Shimon I. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocrine-Related Cancer 2009 16 1017-1027. (doi:10.1677/ERC-08-0269)
133. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M & Degli Uberti EC. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2010 95 968-976. (doi:10.1210/jc.2009-1641)
134. Cooper O, Vlotides G, Fukuoka H, Greene MI & Melmed S. Expression and function of ErbB receptors and ligands in the pituitary. Endocrine-Related Cancer 2011 18 R197-R211. (doi:10.1530/ERC-11-0066)
135. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG & Melmed S. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Research 2008 68 6377-6386. (doi:10.1158/0008-5472. CAN-08-0508)
136. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D & Melmed S. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. Journal of Clinical Investigation 2011 121 4712-4721. (doi:10.1172/JCI60417)
137. Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S & Melmed S. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Molecular Endocrinology 2011 25 92-103. (doi:10.1210/me.2010-0353)
138. Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E & Kovacs K. Anti-VEGF therapy in pituitary carcinoma. Pituitary 2012 15 445-449. (doi:10.1007/s11102-011-0346-8)
139. Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J & Francois P. Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary 2013 16 515-522. (doi:10.1007/s11102-012-0448- y)